OBJECTIVE: To determine the effects of two beta-blockers, nebivolol and bisoprolol, on endothelial function in newly diagnosed hypertensive patients. METHODS:Twenty-five hypertensive patients with a mean (+/- SD) age of 45.3+/-11.5 years were randomly assigned to receive either nebivolol or bisoprolol for eight weeks in an open-label, crossover design. Flow-mediated endothelial-dependent vasodilation (FMD) was measured at baseline and after each eight-week treatment period. At the end of each treatment period, 24 h ambulatory blood pressure (BP) monitoring was performed. RESULTS: The effect of the two beta-blockers on BP was similar. The mean FMD before initiation of treatment was 4.14+/-3.55%. After treatment with nebivolol, FMD increased to 8.99+/-4.21%, with a statistically significant difference from baseline (P<0.001). The effect of bisoprolol treatment on FMD was not as dramatic (3.72+/-6.84%), with no statistically significant difference from baseline. Comparing FMD after each therapeutic regimen, nebivolol treatment resulted in a marked increase in the reactivity of the brachial artery (ie, improvement of endothelial function) compared with bisoprolol treatment (P<0.001). CONCLUSION:Nebivolol treatment of untreated hypertensive patients led to a significant improvement in endothelial function compared with bisoprolol treatment, despite the similar effect on BP with either therapeutic agent.
RCT Entities:
OBJECTIVE: To determine the effects of two beta-blockers, nebivolol and bisoprolol, on endothelial function in newly diagnosed hypertensivepatients. METHODS: Twenty-five hypertensivepatients with a mean (+/- SD) age of 45.3+/-11.5 years were randomly assigned to receive either nebivolol or bisoprolol for eight weeks in an open-label, crossover design. Flow-mediated endothelial-dependent vasodilation (FMD) was measured at baseline and after each eight-week treatment period. At the end of each treatment period, 24 h ambulatory blood pressure (BP) monitoring was performed. RESULTS: The effect of the two beta-blockers on BP was similar. The mean FMD before initiation of treatment was 4.14+/-3.55%. After treatment with nebivolol, FMD increased to 8.99+/-4.21%, with a statistically significant difference from baseline (P<0.001). The effect of bisoprolol treatment on FMD was not as dramatic (3.72+/-6.84%), with no statistically significant difference from baseline. Comparing FMD after each therapeutic regimen, nebivolol treatment resulted in a marked increase in the reactivity of the brachial artery (ie, improvement of endothelial function) compared with bisoprolol treatment (P<0.001). CONCLUSION:Nebivolol treatment of untreated hypertensivepatients led to a significant improvement in endothelial function compared with bisoprolol treatment, despite the similar effect on BP with either therapeutic agent.
Authors: Andreas J Flammer; Frank Hermann; Peter Wiesli; Beat Schwegler; Rémy Chenevard; David Hürlimann; Isabella Sudano; Steffen Gay; Michel Neidhart; Walter Riesen; Frank Ruschitzka; Thomas F Lüscher; Georg Noll; Roger Lehmann Journal: J Hypertens Date: 2007-04 Impact factor: 4.844
Authors: Lars Rydén; Eberhard Standl; Małgorzata Bartnik; Greet Van den Berghe; John Betteridge; Menko-Jan de Boer; Francesco Cosentino; Bengt Jönsson; Markku Laakso; Klas Malmberg; Silvia Priori; Jan Ostergren; Jaakko Tuomilehto; Inga Thrainsdottir; Ilse Vanhorebeek; Marco Stramba-Badiale; Peter Lindgren; Qing Qiao; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; John Camm; Veronica Dean; Jaap Deckers; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; João Morais; Ady Osterspey; Juan Tamargo; José Luis Zamorano; Jaap W Deckers; Michel Bertrand; Bernard Charbonnel; Erland Erdmann; Ele Ferrannini; Allan Flyvbjerg; Helmut Gohlke; Jose Ramon Gonzalez Juanatey; Ian Graham; Pedro Filipe Monteiro; Klaus Parhofer; Kalevi Pyörälä; Itamar Raz; Guntram Schernthaner; Massimo Volpe; David Wood Journal: Eur Heart J Date: 2007-01 Impact factor: 29.983
Authors: V Palmieri; G Storto; E Arezzi; T Pellegrino; M Mancini; G Di Minno; A L Ferrara; A Cuocolo; A Celentano Journal: J Hum Hypertens Date: 2005-12 Impact factor: 3.012
Authors: D S Celermajer; K E Sorensen; V M Gooch; D J Spiegelhalter; O I Miller; I D Sullivan; J K Lloyd; J E Deanfield Journal: Lancet Date: 1992-11-07 Impact factor: 79.321
Authors: Giuseppe Mansia; Guy De Backer; Anna Dominiczak; Renata Cifkova; Robert Fagard; Giuseppe Germano; Guido Grassi; Anthony M Heagerty; Sverre E Kjeldsen; Stephane Laurent; Krzysztof Narkiewicz; Luis Ruilope; Andrzej Rynkiewicz; Roland E Schmieder; Harry A Struijker Boudier; Alberto Zanchetti Journal: Blood Press Date: 2007 Impact factor: 2.835